Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial - McGuire, DK; Busui, RP; Deanfield, J (Diabetes Obes Metab, 2023)